New study establishes criteria to detect ovarian cancer in asymptomatic postmenopausal women

Reporting on the largest study of its kind today at the Society of Gynecologic Oncologists 37th Annual Meeting on Women's Cancer, researchers presented new criteria for detecting ovarian cancer malignancy in postmenopausal asymptomatic women, 55 to 74 years old. Utilizing the new criteria, researchers determined that they could accurately predict 93 percent of the advanced ovarian cancers and 87 percent of the early ovarian cancers in asymptomatic women enrolled in an annual screening program and found to have an abnormal screen.

The study, "Determining the Risk of Ovarian Malignancy in Postmenopausal Women with Abnormal Findings in the PLCO Screening Trial: A Guide for Physicians," was led by Edward E. Partridge, M.D., University of Alabama at Birmingham, Birmingham, AL.

"Until we have an accurate screening test to identify ovarian cancer in asymptomatic women, we must have guidelines to help doctors evaluate common test abnormalities and detect the malignancy with as much precision as possible," said, Dr. Partridge. "The results of this study are immediately useful for guiding interpretation of ultrasound and CA-125 abnormalities in asymptomatic postmenopausal women."

Early diagnosis of ovarian cancer is vital to reducing mortality. This is the largest prospective cancer screening study to evaluate the risk of malignancy in an exclusively postmenopausal population, ages 55-74, when there are no symptoms. This study is particularly noteworthy because the described screening tests (ultrasound and CA-125) are immediately available to women today.

"The dilemma we face with screening for a disease with low prevalence, like ovarian cancer, is false positive results," commented Dr. Andrew Berchuck, co-director of the Breast/Ovarian Cancer Program of the Duke University Comprehensive Cancer Center. "This study is important because it provides guidelines to better interpret the ultrasound and CA 125 testing we have available. Accurate interpretation of test results could ultimately help to save the lives of postmenopausal women who do not present with symptoms but have ovarian cancer, as well as save women who receive ambiguous results from invasive surgery when there is no real malignancy."

"These new guidelines are a significant step forward in the fight against women's cancers," explained Dr. Partridge. "We hope this will encourage further efforts to validate and refine these criteria in other populations so more women can be properly diagnosed and treated for ovarian cancer."

Ovarian cancer is the leading cause of death from gynecologic malignancies, according to the American Cancer Society. Annually, over 22,000 women in the U.S. will develop ovarian cancer and more than 16,000 will die from this disease.

Science Overview
Results from the first three years of The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trials were reviewed to establish scoring criteria for distinguishing malignant from benign processes. Women enrolled in the study had annual screening for lung, colorectal and ovarian cancer. Although historically a CA-125 level over 35 has been considered abnormal, the authors found that a CA-125 of greater than 65 was the best predictor of ovarian cancer in a postmenopausal asymptomatic woman with an initial abnormal screen. In follow-up screening the following criteria, applied in a hierarchical manner, appear to be accurate at detecting malignancy:

  • CA-125 > 65;
  • Or a CA-125 increase of > 40 points;
  • Or a CA-125 change of > 10 with an ovary/cyst > 3 cm:
  • Or an ovary/cyst change of > 6.5 cm.

Using the above criteria for a single screen, 15 of the 20 cancers in the initial or baseline screening group (T0) would have been detected. The study found that subsequent annual screenings provided the opportunity to compare current CA-125 levels and/or transvaginal ultrasounds (TVU) findings with the previous screen. Utilizing the above criteria for distinguishing benign from malignant masses in women with more than one screen, doctors would have been able to detect all 29, or 100 percent of the women with invasive cancer.

"Determining the Risk of Ovarian Malignancy in Postmenopausal Women with Abnormal Findings in the PLCO Screening Trial: A Guide for Physicians," was conducted by Edward E. Partridge, M.D., University of Alabama at Birmingham, Birmingham, AL; Robert T. Greenlee, Marshfield Clinic Research Foundation, Marshfield, WI; Thomas L. Riley, Information Management Services, Inc., Rockville, MD; Craig Williams, Information Management Services, Inc., Rockville, MD; Lawrence R. Ragard, Westat, Rockville, MD; Jian-Lun Xu, National Cancer Institute, Rockville, MD; Saundra S. Buys, Huntsman Cancer Institute, Salt Lake City, UT; and Philip C. Prorok, National Cancer Institute, Rockville, MD.

###

The 2006 Annual Meeting on Women's Cancer is the premier educational and scientific event for physicians and health care professionals involved in the field of gynecologic oncology and is being held March 22X26 at the Palm Springs Convention Center in Palm Springs, California. For more information visit, www.sgo.com.

About SGO
The SGO is a national medical specialty organization of physicians who are trained in the comprehensive management of women with malignancies of the reproductive tract. Its purpose is to improve the care of women with gynecologic cancer by encouraging research, disseminating knowledge which will raise the standards of practice in the prevention and treatment of gynecologic malignancies and cooperating with other organizations interested in women's health care, oncology and related fields. The Society's membership is primarily comprised of gynecologic oncologists, as well as other related medical specialists such as, medical oncologists, radiation oncologists and pathologists. SGO members provide multidisciplinary cancer care including chemotherapy, radiation therapy, supportive care and surgery. More information on the SGO can be found at www.sgo.com.


Last reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
    Published on PsychCentral.com. All rights reserved.

 

 

Most of the things worth doing in the world had been declared impossible before they were done.
~ Supreme Court Justice Louis D. Brandeis
 
Stumble This Article Print Email
Subscribe to Our Weekly Newsletter

Users Online: 13570
Join Us Now!



 




Find a Therapist
Enter ZIP or postal code